» Articles » PMID: 29914597

Global Tuberculosis Targets and Milestones Set for 2016-2035: Definition and Rationale

Overview
Specialty Pulmonary Medicine
Date 2018 Jun 20
PMID 29914597
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Global tuberculosis (TB) targets were set as part of the World Health Organization's End TB Strategy (2016-2035) and the Sustainable Development Goals (2016-2030).

Objective: To define and explain the rationale for these targets.

Design: Scenarios for plausible reductions in TB deaths and cases were developed using empirical evidence from best-performing countries and modelling of the scale-up of under-used interventions and hypothetical TB vaccines. Results were discussed at consultations in 2012 and 2013. A final proposal was presented to the World Health Assembly in 2014 and unanimously endorsed by all Member States.

Results: The 2030 targets are a 90% reduction in TB deaths and 80% reduction in TB incidence compared with 2015 levels. The 2035 targets are for reductions of 95% and 90%, respectively. A third target-that no TB-affected households experience catastrophic costs due to the disease by 2020-was also agreed.

Conclusion: The global TB targets and milestones set for the period 2016-2035 are ambitious. Achieving them requires concerted action on several fronts, but two things are fundamental: 1) progress towards universal health coverage to ensure that everyone with TB can access high-quality treatment; and 2) substantial investment in research and development for new tools to prevent TB disease among the approximately 1.7 billion people infected.

Citing Articles

Clustering and modeling joint-trajectories of HIV/AIDS and tuberculosis mortality rates using bayesian multi-process latent growth model: A global study from 1990 to 2021.

Mobaderi T, Kazemnejad A, Salehi M BMC Infect Dis. 2025; 25(1):330.

PMID: 40065233 PMC: 11892175. DOI: 10.1186/s12879-025-10715-x.


Estimating the health and macroeconomic burdens of tuberculosis in India, 2021-2040: A fully integrated modelling study.

Keogh-Brown M, Sumner T, Sweeney S, Vassall A, Jensen H PLoS Med. 2024; 21(12):e1004491.

PMID: 39666614 PMC: 11637336. DOI: 10.1371/journal.pmed.1004491.


Unlocking the potential of miRNAs in detecting pulmonary tuberculosis: prospects and pitfalls.

Arya R, Kumar S, Vinetz J, Kim J, Chaurasia R Expert Rev Mol Med. 2024; 26:e32.

PMID: 39639643 PMC: 11629464. DOI: 10.1017/erm.2024.29.


Detection of Rifampicin Resistance rpoB Gene Using GeneXpert MTB/RIF Assay in Pulmonary Tuberculosis Cases at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia.

Sharew B, Berhan A, Almaw A, Erkihun M, Tiruneh T, Kiros T J Clin Lab Anal. 2024; 38(22):e25111.

PMID: 39387506 PMC: 11584306. DOI: 10.1002/jcla.25111.


Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity.

Shi Z, Zhou L, Wang X, Zhang Z, Kong L, Zhang Y Arch Microbiol. 2024; 206(8):352.

PMID: 39012499 DOI: 10.1007/s00203-024-04033-0.


References
1.
Steingart K, Schiller I, Horne D, Pai M, Boehme C, Dendukuri N . Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014; (1):CD009593. PMC: 4470349. DOI: 10.1002/14651858.CD009593.pub3. View

2.
Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias H . WHO's new end TB strategy. Lancet. 2015; 385(9979):1799-1801. DOI: 10.1016/S0140-6736(15)60570-0. View

3.
Dye C, Bassili A, Bierrenbach A, Broekmans J, Chadha V, Glaziou P . Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis. 2008; 8(4):233-43. DOI: 10.1016/S1473-3099(07)70291-8. View

4.
Enarson D, Grzybowski S . Incidence of active tuberculosis in the native population of Canada. CMAJ. 1986; 134(10):1149-52. PMC: 1491042. View

5.
STYBLO K, Meijer J, Sutherland I . [The transmission of tubercle bacilli: its trend in a human population]. Bull World Health Organ. 1969; 41(1):137-78. PMC: 2427401. View